, Nov. 5, 2010
/PRNewswire-FirstCall/ -- GenVec, Inc. (Nasdaq: GNVC) announced today that NASDAQ has approved its application to transfer its stock listing to The Nasdaq Capital Market (the "Capital Market") from The Nasdaq Global Market, effective at the opening of business on Monday, November 8, 2010
. The company's common stock will continue to be traded under the symbol "GNVC". The Nasdaq Capital Market is a continuous trading market that operates in substantially the same manner as the Nasdaq Global Market.
GenVec, Inc. is a biopharmaceutical company developing novel therapeutic drugs and vaccines. GenVec uses proprietary drug discovery and development technologies to support a portfolio of product programs that address the prevention and treatment of a number of major diseases. In collaboration with Novartis, GenVec is developing novel treatments for hearing loss and balance disorders. GenVec also develops and is evaluating the potential of TNFerade for the treatment of certain cancers and is developing vaccines for infectious diseases including influenza, HIV, malaria, foot-and-mouth disease, respiratory syncytial virus (RSV), and HSV-2. Additional information about GenVec is available at www.genvec.com and in the Company's various filings with the Securities and Exchange Commission.
Douglas J. Swirsky
SOURCE GenVec, Inc.